Research and treatment efforts for Alzheimer’s disease have traditionally focused on what happens in the brain. But there has recently been a growing body of evidence that what happens elsewhere in the body—such as the microbial population of the gut—could play a key role in the disease as well.
A new project led by Massachusetts General Hospital’s Deepak Vijaya Kumar,
Building on a Game Changing Insight
Kumar’s research is an extension of key scientific insight that came out of the Genetics Research and Aging Unit at Mass General several years ago
In a 2016 study, a team led by Robert D. Moir, PhD, and Rudolph E. Tanzi, PhD, demonstrated that amyloid beta—long thought to function solely as a harmful byproduct of Alzheimer’s disease—actually plays a protective role by entrapping microbes that cross the blood-brain barrier to stop them from harming the brain.
Researchers have previously shown that AD mice (mouse models of Alzheimer’s disease genetically engineered to develop the hallmark plaques and tangles of the disease) also develop a different balance of bacteria in the gut than healthy mice.
Scientists have also demonstrated AD mice raised in a sterile environment, with little or no microbes in their intestines, had significantly lower doses of amyloid in the brain and did not develop plaques.
A Promising New Model of the Disease
Kumar will now investigate how changes to bacteria in the gut affect disease progression in a new mouse model—one that is bioengineered to produce the amyloid protein, but not genetically destined to develop = plaques and tangles.
“If these mice have a lot of amyloid beta in the brain in a soluble form, is it possible to manipulate the gut ecosystem and make them develop plaques? That’s going to be the challenge.”
Insights into how bacterial changes in the gut correlate with Alzheimer’s disease could help with earlier disease diagnosis—it may be that these changes occur before individuals start experiencing cognitive issues such as memory loss.
It could also point to new treatment strategies that indirectly slow or halt the progression of plaques and tangles in the brain by restoring a healthy microbial population to the gut.
Could Fecal Transplants Help?
One of the most effective strategies for restoring balance to an unbalanced gut microbiome is through fecal microbiota transplant (FMTs)—essentially transplanting fecal material from a healthy intestine into an unhealthy one.
While the process may not sound too appealing, fecal transplants have already been successful in treating some human intestinal infection caused by Clostridium difficile.
Kumar will also use the new mouse model to test FMTs as a treatment.
Kumar has created a new term to describe his unique niche in the research world at the intersection of neurology and microbiology—neuromicrobiology.
“I think this is the best field I could be
About Cure Alzheimer’s Fund
Cure Alzheimer’s Fund is a non-profit organization dedicated to funding research with the highest probability of preventing, slowing or reversing Alzheimer’s disease. Learn more
About the Mass General Research Institute
Massachusetts General Hospital is home to the largest hospital-based research program in the United States. Our researchers work side-by-side with physicians to develop innovative new ways to diagnose, treat and prevent disease.
Support our research